Assessment of serum interleukin 6 level in patients with chronic obstructive pulmonary disease: is it related to disease severity?

Elnaby, Esmat A. Abd; Elnaiem, Samah S. Abd; Mostafa, Amira; Sabry, Dina; Alnaggar, Alshaimaa R.; Haswa, Mohamed K

doi:10.4103/ejb.ejb_50_19

Cited by 2 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interleukin-6 decreased in the patients that enrolled in this study and reduced to a lesser extent in non-responder chronic bronchitis patients. Despite the IL-6 had a negative association with FEV1 (%) (15), many studies proved a positive correlation between IL-6 as inflammatory marker and disease severity, prognosis and increased exacerbation of patients with COPD (24)(25)(26) .…”

Section: Discussionmentioning

confidence: 99%

Evaluation of C-Reactive Protein, Interleukin-6, and Neutrophil-Lymphocyte Ratio as Inflammatory Markers in Patients with Chronic Bronchitis Taking Oral Prednisolone in Maysan City Population

Taha yaseen,

Hanna,

Hadi

2024

AJPS

View full text Add to dashboard Cite

Background: Clinically, chronic bronchitis is defined as a persistent cough lasting at least three months over the course of two years in a patient where all other causes have been excluded. It is almost invariably described as a feature of Chronic Obstructive Pulmonary Disease (COPD) secondary to smoking. Patients and methods: Ninety-five Iraqi patients newly diagnosed with chronic bronchitis were selected to participate in this study. Sixty patients (40 male and 20 female) were enrolled in the current study their ages were ranged from (40-65 years). The patients were divided into two groups, in the first group (responders’ group) the patients were responded to oral prednisolone therapy, and in the other group the patients were not responded to oral prednisolone therapy (non-responders’ group). The assessment of responsiveness to prednisolone will be according to ATS (American Thoracic Society) which define the responders as those with a response of >12% baseline and >200 ml of FEV1. This study is a prospective observational clinical trial was carried out in thoracic consultant clinic at Al- Sader teaching Hospital in Maysan city from March 2022 until March 2023. The prednisolone tablets given in a dose of 30mg /day for 14 days. Aim of the study: The current study was aimed to identify the association of the inflammatory markers C-reactive protein, interleukin-6 and neutrophils-lymphocytes ratio with the response of chronic bronchitis patients to oral prednisolone therapy. Results and Conclusions: CRP, IL-6, and NLR consider as good predictive markers (P value<0.001) to determine the responsivity of patients with chronic bronchitis taking oral prednisolone tablets for 14 days.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of C-Reactive Protein, Interleukin-6, and Neutrophil-Lymphocyte Ratio as Inflammatory Markers in Patients with Chronic Bronchitis Taking Oral Prednisolone in Maysan City Population

Taha yaseen,

Hanna,

Hadi

2024

AJPS

View full text Add to dashboard Cite

show abstract

Assessment of association between interleukin 6 gene variant and its serum level in chronic obstructive pulmonary disease in a sample of Egyptian population

Ashraf,

Ramzi,

Mostafa

et al. 2024

Egypt J Chest Dis Tuberc

View full text Add to dashboard Cite

Background Researches in chronic obstructive pulmonary disease (COPD) had shown signs of inflammation with inflammatory markers that had pivotal role in COPD. some studies proposed that elevated serum interleukin-6 (IL-6) is associated with negative impact on lung functions but up to our knowledge, no studies were performed to correlate the genotypes of IL-6 with COPD patients in Egyptian and middle east populations. Objectives To study both the correlation of serum level of IL-6 as well as its gene variant (also known as G174C)) as possible genetic marker for COPD patients in Egyptian patients. Materials and methods This study is case-control that enrolled ninety participants; it consisted of two groups. Group I included 45 patients who were diagnosed as stable COPD; Group II included 45 healthy participants. After full clinical and pulmonary functions assessment of all participants, blood samples were collected from both groups for the detection serum level of IL-6 by ELISA and the detection of IL6 variant by TaqMan Real-Time PCR. Results Our study revealed that there was statistically significant increase in serum level of interleukin-6 in COPD patients compared to normal individuals (P value <0.001) and the presence of G/G variant of interleukin 6 gene in COPD patients more than normal subjects with frequency of 84.4% and 53.3% for COPD patients and healthy controls respectively. There was significant correlation between the serum level of interleukin-6 and COPD staging (P value <0.007). Conclusion The genotype GG variant of IL6 contributes to the prediction of COPD and may be used as a marker for the prediction of COPD risk in Egyptian population. Serum level of IL6 is markedly higher in COPD patients and can be used as a parameter of correlation with COPD stages.

show abstract

Assessment of serum interleukin 6 level in patients with chronic obstructive pulmonary disease: is it related to disease severity?

Cited by 2 publications

References 17 publications

Evaluation of C-Reactive Protein, Interleukin-6, and Neutrophil-Lymphocyte Ratio as Inflammatory Markers in Patients with Chronic Bronchitis Taking Oral Prednisolone in Maysan City Population

Evaluation of C-Reactive Protein, Interleukin-6, and Neutrophil-Lymphocyte Ratio as Inflammatory Markers in Patients with Chronic Bronchitis Taking Oral Prednisolone in Maysan City Population

Assessment of association between interleukin 6 gene variant and its serum level in chronic obstructive pulmonary disease in a sample of Egyptian population

Contact Info

Product

Resources

About